TCRT - alaunos.com Forward Price-to-Revenue Multiple

Alaunos Therapeutics (TCRT) is developing innovative TCR-T cancer therapies, leveraging clinic partnerships to support R&D and cash flows. The firm's forward P/S, where the current parameter is 583.70, highlights liquidity decline risks amid US export bans to Asia. Restructuring and the suspension of key programs have severely weakened competitive advantages, leaving only limited patent value.

Alaunos Therapeutics, Inc. - TCRT Projected Price to Revenue (period 07/04/2022 - 05/16/2026)

Alaunos Therapeutics, Inc. - analytical breakdowns and key metrics (TCRT)

- market price and analyst price targets:

Price Chart Alaunos|TCRT - Price Target Chart

- market capitalization statistics:

Market Valuation Alaunos Therapeutics Inc.|TCRT - Value Adjusted for Debt and Cash

- business book valuation details:

Book Value per Share Alaunos Therapeutics|TCRT - Book Value of Business|Market Capitalization to Book Value Ratio alaunos.com|TCRT - Company Assets

- debt and solvency information:

- financial results and valuation multiples details:

TCRT - Final Profit|Projected Future Earnings Alaunos Therapeutics|TCRT - Market Cap to Earnings|Future Price to Earnings Alaunos Therapeutics|TCRT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Alaunos Therapeutics|TCRT - Operating profit EBITDA|Earnings per share for the last twelve months Alaunos Therapeutics|TCRT - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months alaunos.com|TCRT - Earnings per share growth rate in current year|Earnings growth forecast for next year Alaunos Therapeutics

- revenue and sales proceeds data:

TCRT - Revenue and Sales Volume|Company Projected Revenue Alaunos|TCRT - Price-to-Revenue Ratio|Forward P/S Multiple Alaunos Therapeutics

Initial company analysis:Alaunos Therapeutics, Inc. (TCRT)

The assessment of the margin of safety for Alaunos Therapeutics (TCRT) is based on the ratio of market capitalization to expected revenue, which determines the value of each unit of future sales. Analyzing the company's projected P/S chart, an investor can see the balance between growth potential and the risk of a price collapse due to a high cash burn rate and the threats of clinical trial suspensions for its cell therapy.

Key competitors

Price-to-Projected Revenue Ratio Legend Biotech Inc. LEGN|Sana Biotechnology - Price-to-Projected Revenue Ratio|AUTL: Forward Price-to-Revenue Multiple|Forward Price to Sales ALLO (Allogene Therapeutics)|RNAC: Forward P/S Multiple|Projected Price to Revenue Cellectis SA CLLS|CRBU (cariboubio.com) - Forward P/S Multiple|Market Cap to Projected Revenue TIL (Instil Bio, Inc)|Price-to-Projected Revenue Ratio Genenta (GNTA)|Century Therapeutics, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple JSPR (Jasper Therapeutics, Inc.)|sentibio.com (SNTI) - Market Cap to Future Revenue Ratio|ADAP: Forward Price-to-Revenue Multiple|Forward Price to Sales CERO (CERo Therapeutics Holdings, Inc.)|ACHL (achillestx.com) - Forward Price-to-Revenue Multiple|CRGX: Price to Expected Revenue Ratio|PSTX (Poseida Therapeutics, Inc.) - Forward P/S Multiple|TSVT: Forward Price to Sales|Forward P/S Multiple GRCL